|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01EB02
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:blackBoxWarning
|
interstitial lung disease
hepatic failure
|
|
gptkbp:CASNumber
|
183321-74-6
|
|
gptkbp:chemicalFormula
|
C22H23N3O4
|
|
gptkbp:contraindication
|
hypersensitivity to erlotinib
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Roche
gptkb:OSI_Pharmaceuticals
|
|
gptkbp:drugClass
|
protease inhibitor
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
36 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:erlotinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tarceva
|
|
gptkbp:indication
|
locally advanced, unresectable or metastatic pancreatic cancer
locally advanced or metastatic non-small cell lung cancer
|
|
gptkbp:interactsWith
|
gptkb:proton_pump_inhibitors
gptkb:warfarin
smoking
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Genentech
gptkb:Roche
gptkb:OSI_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
gptkb:EGFR_tyrosine_kinase_inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP1A2, CYP1A1)
|
|
gptkbp:molecularWeight
|
393.44 g/mol
|
|
gptkbp:pregnancyCategory
|
D
D (US)
|
|
gptkbp:prescribes
|
adults
|
|
gptkbp:proteinBinding
|
93%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
anorexia
fatigue
rash
|
|
gptkbp:tradenameOf
|
gptkb:erlotinib
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
pancreatic cancer
|
|
gptkbp:bfsParent
|
gptkb:Roche
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:bfsLayer
|
6
|